Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
iRhythm Technologies, Inc.
IRTC
NASDAQ·Healthcare·Medical - Devices·Mkt cap $4.1B
$124.90
▲ +0.30%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$100.85 - $212.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 12.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Wire-free, patch-based design superior to traditional Holter monitors
- Proprietary cloud analytics platform with AI-driven arrhythmia detection
- Strategic partnership with Verily Life Sciences for next-gen product development
- Established market presence and physician adoption in cardiac monitoring
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Rising prevalence of atrial fibrillation and cardiac arrhythmias
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Strong
+6.6% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying IRTC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
APR 30, 2026
Reported EPS of -$0.43 vs -$0.56 consensus (+23.2% surprise). Revenue of $199.4M vs $194.1M expected (+2.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+23.2%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+24%
+20%
+26%
+31%
+27%
+26%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$148.0M
$147.5M
$164.3M
$158.7M
$186.7M
$192.9M
$208.9M
$199.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
-7.0%
Wall Street consensus
10 analysts · 90% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
90%
Hold
10%
Sell
0%
Median Price Target
$175.00
▲ +40.1% vs $124.90
Latest: Bank of America · May 18, 2026
6 analysts covering